SCHEMBL6449706

SCHEMBL6449706

COc1cc2c(cc1OC)[C@@H]1CCCC[C@@H]1N=C2c1cccs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB2 Q9UBS0 2/20 0.41
HSD17B10 Q99714 4/20 0.39
MAPK1 P28482 4/20 0.39
TSHR P16473 2/20 0.39
KDM4E B2RXH2 8/20 0.39
ALDH1A1 P00352 7/20 0.39
HPGD P15428 3/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
TP53 P04637 1/20 0.39
PDE2A O00408 1/20 0.37
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37
LMNA P02545 3/20 0.36
GAA P10253 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CA2 P00918 1/20 0.36
PDE4D Q08499 1/20 0.36
MAPT P10636 3/20 0.36
HTT P42858 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6449709 1.00 RPS6KB2 (0.41) RPS6KB2HSD17B10MAPK1TSHRKDM4E
SCHEMBL6449710 1.00 RPS6KB2 (0.41) RPS6KB2HSD17B10MAPK1TSHRKDM4E
SCHEMBL6450450 0.82 PDE4D (0.38) HSD17B10MAPK1TSHRKDM4EALDH1A1
SCHEMBL6450454 0.82 PDE4D (0.38) HSD17B10MAPK1TSHRKDM4EALDH1A1
SCHEMBL6450452 0.82 PDE4D (0.38) HSD17B10MAPK1TSHRKDM4EALDH1A1
SCHEMBL6442363 0.80 S1PR1 (0.39) KDM4EALDH1A1GAAPDE4DMAPT
SCHEMBL6442355 0.80 S1PR1 (0.39) KDM4EALDH1A1GAAPDE4DMAPT
SCHEMBL6442359 0.80 S1PR1 (0.39) KDM4EALDH1A1GAAPDE4DMAPT
SCHEMBL6453982 0.79 PDE4D (0.40) MAPK1PDGFRBPDGFRAPDE4DHTT
SCHEMBL6453976 0.79 PDE4D (0.40) MAPK1PDGFRBPDGFRAPDE4DHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884802-B2 6-heteroarylphenanthridines ALTANA PHARMA AG (DE) 2005-04-26 US disclosed
US-20040038979-A1 Treating airway disorders such as asthma. ALTANA PHARMA AG (DE) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038979-A1 Treating airway disorders such as asthma. PTGER4, PDE4B, PDE4A RPS6KB2 1837/4885HSD17B10 1564/4885MAPK1 3164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.